Company Filing History:
1 out of 321 
1 out of 4 Years Active: 2015
Title: Sun Jung Cho: Innovator in Autoimmune Disease Treatment
Introduction
Sun Jung Cho is a prominent inventor based in Suwon-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the treatment of autoimmune diseases. His innovative work has led to the development of a unique therapeutic approach that targets key inflammatory pathways.
Latest Patents
Sun Jung Cho holds a patent for a dual antagonist for TNF-α and IL-21, aimed at preventing and treating autoimmune diseases. The invention involves a TNFR2-IL21R fusion protein that acts as a double antagonist to TNF-alpha and IL-21. This composition is particularly effective in reducing the secretion of inflammatory cytokines and increasing the secretion of anti-inflammatory cytokines. It also suppresses the differentiation of osteoclasts more effectively than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein has demonstrated excellent treatment effects on arthritis in a CIA mouse model and enhances the expression of Treg cells, which are crucial for immune suppression. This innovation holds promise as an active ingredient for compositions aimed at preventing and treating autoimmune diseases.
Career Highlights
Throughout his career, Sun Jung Cho has worked with esteemed institutions such as the Korea Research Institute of Bioscience and Biotechnology and the Industry-Academic Cooperation Foundation at the Catholic University of Korea. His research has focused on developing novel therapeutic strategies to combat autoimmune conditions.
Collaborations
Sun Jung Cho has collaborated with notable colleagues, including Young Woo Park and Ki Won Jo. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Sun Jung Cho's innovative work in the field of autoimmune disease treatment exemplifies the impact of biotechnology on healthcare. His contributions through the development of the TNFR2-IL21R fusion protein highlight the potential for new therapeutic approaches in managing autoimmune diseases.